"Consegna (ASX: CGP) continues to validate the potential to bring the Aspen Medisys nanoparticle thermotherapy platform to market with expressions of interest from Europe-based parties wanting to commercialise the technology. As a result, the company has extended the period of evaluation of Aspen Medisys 29 October 2012 to pursue the expressions of interest received.
Consegna acquired Aspen Medisys in December 2011 and its nano-particle thermotherapy platform technology, which has shown promise as a new treatment for cancer.
Under the terms of the acquisition agreement for Aspen Medisys, Consegna had a period of six months to evaluate the technology.
The vendors have accepted the four month extension, with a further nominal deposit payment in scrip of $141,000 and the balance of shares from the December agreement payable should Consegna agree to complete the acquisition of the asset."
- http://www.proactiveinvestors.com.au/companies/news/30894/consegna-aspen-medisys-technology-potential-attracts-europe-based-parties-to-commercialise-30894.html
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)